NeuBase Therapeutics, Inc.: 10-K filed 2013-12-27
What NeuBase Therapeutics, Inc. reported in its annual report filed 2013-12-27 (fiscal FY 2013): 25 published measures, 73 facts as tagged in accession 0001387131-13-004795.
This filing
- Form
- 10-K (annual report)
- Filed
- 2013-12-27
- Fiscal period
- fiscal FY 2013
- Accession
- 0001387131-13-004795 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuBase Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 5,743,865 | USD | |
| At 2012-09-30 | 3,517,420 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 479,737 | USD | |
| At 2012-09-30 | 1,091,195 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 5,264,128 | USD | |
| At 2012-09-30 | 2,426,225 | USD | |
| At 2011-09-30 | -4,781,753 | USD | |
| At 2010-09-30 | -382,457 | USD | |
| At 2009-09-30 | 612,685 | USD | |
| At 2008-09-30 | 33,195 | USD | |
| At 2007-09-30 | -263,116 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | -5,652,488 | USD | 365 |
| 2007-10-01 to 2013-09-30 | -12,554,136 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | -1,454,884 | USD | 366 |
| 2010-10-01 to 2011-09-30 | -5,101,519 | USD | 365 |
| 2009-10-01 to 2010-09-30 | 494,377 | USD | 365 |
| 2008-10-01 to 2009-09-30 | -864,449 | USD | 365 |
| 2007-10-01 to 2008-09-30 | 24,827 | USD | 366 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | -2,689,687 | USD | 365 |
| 2007-10-01 to 2013-09-30 | -6,904,487 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | -1,753,829 | USD | 366 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2007-10-01 to 2013-09-30 | 58,421 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 33,403 | USD | 366 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 5,180,169 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 11,700,028 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 3,949,859 | USD | 366 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2007-10-01 to 2013-09-30 | 130,079 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | -33,403 | USD | 366 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -21,628,748 | USD | |
| At 2012-09-30 | -21,628,748 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 29,755 | USD | |
| At 2012-09-30 | 43,111 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 746,262 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 1,831,830 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 406,267 | USD | 366 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | -4,620,916 | USD | 365 |
| 2007-10-01 to 2013-09-30 | -11,752,790 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | -3,286,408 | USD | 366 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 5,168,245 | USD | |
| At 2012-09-30 | 2,850,655 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 4,689 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 56,229 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 1,817 | USD | 366 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 479,737 | USD | |
| At 2012-09-30 | 1,091,195 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 4,620,916 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 11,752,790 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 3,286,408 | USD | 366 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 2,610,120 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 5,036,335 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 1,625,695 | USD | 366 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 19,741,541 | shares | |
| At 2012-09-30 | 15,752,896 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 39,444,988 | USD | |
| At 2012-09-30 | 30,966,379 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | -5,652,488 | USD | 365 |
| 2007-10-01 to 2013-09-30 | -13,232,549 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | -1,454,884 | USD | 366 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 312,541 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 1,445,909 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 135,552 | USD | 366 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 13,356 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 28,666 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 9,456 | USD | 366 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 77,789 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 254,135 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 78,273 | USD | 366 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | 90,759 | USD | 365 |
| 2007-10-01 to 2013-09-30 | 154,284 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 112 | USD | 366 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-10-01 to 2013-09-30 | -1,031,572 | USD | 365 |
| 2007-10-01 to 2013-09-30 | -1,479,759 | USD | 2192 |
| 2011-10-01 to 2012-09-30 | 1,831,524 | USD | 366 |
Inspect the source
- Entity
- NeuBase Therapeutics, Inc. / CIK 0001173281
- Captured
- SEC response SHA-256
0e0882fa147fcb0a3e5f3af54573abe947d9ade4d42095debd16c2d62da36e79
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001173281.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))